PRKDC and cancer: Relative to Top2 inhibition alone, immunohistochemical staining and flow cytometry analysis indicate enhanced DNA damage in non-proliferating and G1 phase cancer and normal tissue cells in treatments when combining etoposide and DNA-PK inhibitors.